Agreed, bees and other insect pollinators are under threat globally from multiple human pressures. If pollinators disappear completely from an ecosystem, their loss will affect the structure of tho…

Mineralys Therapeutics (Nasdaq: MLYS) issued a corporate update announcing clinical and regulatory milestones for lorundrostat, its investigational antihypertensive.Key points: the company filed an NDA in late 2025 after completing three positive clinical trials in 2025; two global pivotal Phase 3 trials met primary endpoints; the Phase 2 Explore-CKD trial met its primary systolic blood pressure endpoint and reduced proteinuria; enrollment for Explore-OSA finished in Q3 2025 with topline results expected in Q1 2026. An open-label extension continues to collect long-term safety and efficacy data.

Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics.

Rapt Therapeutics (NASDAQ:RAPT – Free Report) – Lifesci Capital lowered their FY2025 EPS estimates for shares of Rapt Therapeutics in a research note issued on Thursday, November 6th. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($2.95) per share for the year, down from their prior estimate of ($1.17). Lifesci Capital […]

Apnimed, Inc. announces its participation in the upcoming LifeSci Capital & Sofinnova Partners Growth and Innovation Summit, set for November 17.